Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Granata Bio
AddedFeb 15, 2024
UpdatedJun 18, 2026
Granata Bio

Granata Bio

Series A

Fertility biotech firm specializing in innovative solutions for patients.

HQ
Duxbury, MA, US
Founded
2018
Overview
Compare
Fundraising
Employees
Website

Granata Bio, a fertility biotechnology company, was founded with the mission of developing innovative solutions to address infertility and enhance reproductive health. The company focuses on identifying and advancing biopharmaceuticals that can positively impact women's health in North America. Granata Bio designs development programs that prioritize safety, efficacy, regulatory compliance, and integration into modern fertility clinical practices.

Notably affiliated with leading experts in reproductive health, Granata Bio has garnered attention from prominent investors in the biotech sector. The company has achieved significant milestones in its product development pipeline, contributing to advancements in fertility treatments. Granata Bio's impact is reflected in its commitment to providing comprehensive solutions that go beyond medicine, supporting patients through their fertility journey.

Granata Bio - Similar Companies

Gameto logo

Gameto

gametogen.com

Incept BioSystems logo

Incept BioSystems

Regenerative Bio logo

Regenerative Bio

regen-bio.us

Nora Therapeutics logo

Nora Therapeutics

Hera Biotech logo

Hera Biotech

herabiotech.com

Luca Biologics logo

Luca Biologics

seedhealth.com

Bioincept logo

Bioincept

bioincept.com

INVO Fertility logo

INVO Fertility

invobioscience.com

Curie.Bio logo

Curie.Bio

curie.bio

Petri Bio logo

Petri Bio

petribio.com

Solarea Bio logo

Solarea Bio

solareabio.com

GentiBio logo

GentiBio

gentibio.com

Gradient Pharmaceuticals logo

Gradient Pharmaceuticals

ReproHealth Technologies logo

ReproHealth Technologies

Galatea Bio logo

Galatea Bio

galatea.bio

Granata Bio - Quick Facts

Who are Granata Bio's competitors?

Companies similar to Granata Bio include Gameto, Incept BioSystems, Regenerative Bio and Nora Therapeutics.

When was Granata Bio founded?

Granata Bio was founded in 2018.

Where is Granata Bio's headquarters located?

Granata Bio's headquarters is located in Duxbury, MA, US.

When was Granata Bio's last funding round?

Granata Bio's most recent funding round was for $14M (USD) in January 2024.

How much has Granata Bio raised to-date?

As of Jan 16, 2024, Granata Bio has raised a total of $14.1M (USD).

How many employees does Granata Bio have?

Granata Bio has 5 employees as of Feb 5, 2024.

Granata Bio - Classification

Ownership
  • Private
  • Venture Capital
Technology
  • Biotech
Geographic Exposure
  • Americas
Model
  • Platform
Revenue
  • Recurring
Customer
  • Consumers
  • Enterprise
Main Product
  • Biopharmaceuticals
Tags
  • Biotech
  • Healthtech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541500Computer Systems Design and Related Services
  • 541000Professional, Scientific, and Technical Services
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7371Computer Programming Services
Show 5 more industry codes
NAICS
  • 513200Software Publishers
  • 510000Information
  • 513000Publishing Industries
  • 513210Software Publishers
SIC
  • 7372Prepackaged Software